Cost effectiveness analysis must be used carefully and as part of a comprehensive evaluation of the value a treatment, such as highly effective modulators, provide to people living with cystic fibrosis.
- About the CF Foundation
- Public Policy
- Health Care Reform
- Our Research Approach
- Clinical Trials
- Cystic Fibrosis Foundation Therapeutics (CFFT)
- Genetic Therapies
- Drug Pipeline
- CFTR Modulators
- Care Centers
- North American CF Conference
- Coronavirus (COVID-19)
- Get Involved
- Infection Prevention and Control
- Adult Care
- Patient Assistance
- Researcher Resources
- (-) Our Advocacy Work
A cystic fibrosis diagnosis must not disqualify an individual from life-saving care.
More than 160 organizations join the Cystic Fibrosis Foundation in asking Congress to expand paid family and medical leave for people with chronic conditions, such as cystic fibrosis.
Responding to the Trump administration's recent decision to freeze risk adjustment payments, the Cystic Fibrosis Foundation joined 13 other nonpartisan patient groups to voice disappointment in the latest administrative efforts to undermine adequate and affordable health care for people with pre-existing conditions.
The organizations urge continued protections for patients.
Patient and provider groups urge safeguard for the health and lives of millions of Americans with a bipartisan approach to reform.
Ten patient and provider groups, representing millions of Americans, issued the following statement in response to the release of the nonpartisan Congressional Budget Office's (CBO) scores of two pieces of health care reform legislation currently being considered by the U.S. Senate.
Patient and provider groups urge the Senate to work together in a bipartisan fashion to ensure that Americans have access to affordable health care.
Today, the Senate released a new draft of the Better Care Reconciliation Act (BCRA), including an amendment that would allow insurance companies to offer plans not in compliance with critical patient protections in current law.
Twelve patient/consumer groups urge senate to reject the bill.